Compounds > harmaline

harmaline and isomethyleugenol

harmaline has been researched along with isomethyleugenol in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cobuzzi, RJ; Collins, MA; Neafsey, EJ1
Gonzalez, FJ; Idle, JR; Krausz, KW; Küpfer, A; Yu, AM1
Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A1
Jiang, XL; Shen, HW; Wu, C; Yu, AM1
Bui, PH; Handforth, A; Hankinson, O; Homanics, GE; Quesada, A1

Other Studies

5 other study(ies) available for harmaline and isomethyleugenol

ArticleYear
Differential cytotoxicities of N-methyl-beta-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease.
    Journal of neurochemistry, 1994, Volume: 62, Issue:4

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Cations; Cell Death; Culture Media; Energy Metabolism; Harmaline; Kinetics; L-Lactate Dehydrogenase; Methylation; Molecular Structure; Parkinson Disease; PC12 Cells; Rats

1994
Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1

    Topics: Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; DNA, Complementary; Harmaline; Harmine; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Male; Mass Spectrometry; Methylation; Mice; Mice, Transgenic; Microsomes, Liver; Psychotropic Drugs

2003
Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
    Journal of neurochemistry, 2004, Volume: 89, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cell Line; Cell Survival; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Harmaline; Harmine; Humans; Inhibitory Concentration 50; Kidney; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Methylation; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperazines

2004
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Biochemical pharmacology, 2010, Jul-01, Volume: 80, Issue:1

    Topics: Animals; Area Under Curve; Bufotenin; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Genotype; Half-Life; Harmaline; Hepatocytes; Humans; Isoenzymes; Kinetics; Methoxydimethyltryptamines; Methylation; Mice; Mice, Transgenic; Microsomes, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenotype; Polymorphism, Genetic; Psychotropic Drugs

2010
Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.
    European journal of pharmacology, 2011, May-20, Volume: 659, Issue:1

    Topics: Animals; Behavior, Animal; Benzimidazoles; Cyclopropanes; Cytochrome P-450 Enzyme System; Disease Models, Animal; Essential Tremor; Gene Deletion; Harmaline; Hydroxylation; Methylation; Mibefradil; Mice; Naphthalenes; Receptors, GABA-A; Structure-Activity Relationship; Testosterone

2011